DRUG INTERACTION
Severity :
Contraindicated
may have an increased immunosuppressive effect when combined with leflunomide
No drug interaction found for abrocitinib and
Contraindicated
budesonide (nasal)
corticosteroids may enhance the immunosuppressive effect of abrocitinib
aspirin
may increase the antiplatelet effect
berotralstat
may enhance the serum concentration of P-glycoprotein inhibitors
digoxin
may increase the immunosuppressive effect
lefamulin
may enhance the serum concentration of P-glycoprotein inhibitors
relugolix
may enhance the serum concentration of P-glycoprotein inhibitors
rimegepant
may enhance the serum concentration of P-glycoprotein inhibitors
budesonide (nasal)
may have an increased immunosuppressive effect when combined with abrocitinib
remdesivir
may decrease the therapeutic effect when combined with COVID-19 vaccine
cOVID-19 vaccine
immunosuppressants may diminish the therapeutic effect of vaccines
deflazacort
may increase the immunosuppressive effect of corticosteroids
prednisolone
may increase the immunosuppressive effect of corticosteroids
fludrocortisone
may increase the immunosuppressive effect of corticosteroids
denosumab
may have an increased immunosuppressive effect when combined with denosumab
aspirin
may have an increased antiplatelet effect when combined with abrocitinib
leflunomide
may have an increased immunosuppressive effect when combined with leflunomide
sipuleucel-T
may decrease the therapeutic effect when combined with sipuleucel-t
cOVID-19 vaccine
may decrease the therapeutic effect when combined with covid-19 vaccine
may have an increased immunosuppressive effect when combined with leflunomide
trimethadione
may diminish the metabolism of each other when combined
Serious Use Alternative
aspirin
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
defibrotide sodium
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
anagrelide
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
cilostazol
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
efalizumab
may increase the immunosuppressive effect of immunosuppressants
pimecrolimus
may increase the immunosuppressive effect of immunosuppressants
tacrolimus
may increase the immunosuppressive effect of immunosuppressants
abatacept
may increase the immunosuppressive effect of immunosuppressants
aspirin
antiplatelet agents increase the antiplatelet effect of abrocitinib
anagrelide
antiplatelet agents increase the antiplatelet effect of abrocitinib
cilostazol
antiplatelet agents increase the antiplatelet effect of abrocitinib
belimumab
may increase the immunosuppressive effect
cladribine
may increase the immunosuppressive effect
efavirenz
may enhance the serum concentration
tanshinone I
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
rosmarinic acid
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
caryophyllene
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
ursolic acid
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
cepharanthine
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
desvenlafaxine
may have an increased antiplatelet effect when combined with Abrocitinib
milnacipran
may have an increased antiplatelet effect when combined with Abrocitinib
nefazodone
may have an increased antiplatelet effect when combined with Abrocitinib
reboxetine
may have an increased antiplatelet effect when combined with Abrocitinib
venlafaxine
may have an increased antiplatelet effect when combined with Abrocitinib
pimecrolimus topical
may have an increased immunosuppressive effect when combined with immunosuppressants
reslizumab
may have an increased immunosuppressive effect when combined with immunosuppressants
primidone
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
phenobarbital
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
carbamazepine
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
efavirenz
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
isoniazid
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
abrocitinib
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
avacopan
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
siponimod
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
pidotimod
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
lipegfilgrastim
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
filgrastim
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
echinacea
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
aldesleukin
abrocitinib: they may increase the immunosuppressive effect of immunostimulants
doxorubicin
may enhance the immunosuppressive effect of immunosuppressants
daunorubicin
may enhance the immunosuppressive effect of immunosuppressants
cabazitaxel
may increase excessive immunosuppressive effects and risk of infection
cladribine
may increase excessive immunosuppressive effects and risk of infection
docetaxel
may increase excessive immunosuppressive effects and risk of infection
enzalutamide
CYP2C19 enhancers (moderate) may reduce the therapeutic efficacy of abrocitinib
blinatumomab
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
floxuridine
when both drugs are combined, there may be an increase in immunosuppressive activity and the risk of severe infection
copanlisib
when both drugs are combined, there may be an increase in the effect of immunosuppressants
zanubrutinib
when both drugs are combined, there may be increase in the effect of immunosuppressants
idarubicin
may enhance the immunosuppressive effect of immunosuppressants
etanercept
it may increase the immunosuppressive effect of immunosuppressants
escitalopram
antiplatelet agents increase the effect of abrocitinib
prasugrel
may increase the toxic effect of anti-platelet agents
adalimumab-aacf
may enhance the immunosuppressive effect of immunosuppressants
guselkumab
may increase the immunosuppressive effect
acalabrutinib
may increase the immunosuppressive effect of immunosuppressants
brodalumab
may increase the immunosuppressive effect of immunosuppressants
mitomycin
may increase the immunosuppressive effect of immunosuppressants
mitoxantrone
may increase the immunosuppressive effect of immunosuppressants
thioguanine
may increase the immunosuppressive effect of immunosuppressants
vilobelimab
may increase the immunosuppressive effect of Immunosuppressive agents
abrocitinib
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
baricitinib
may have an increased immunosuppressive effect when combined with baricitinib
bcg vaccine
may have an increasingly adverse effect when combined with BCG products
Monitor Closely
efalizumab
it may enhance the immunosuppressive effect of immunosuppressants
pimecrolimus
it may enhance the immunosuppressive effect of immunosuppressants
tacrolimus
it may enhance the immunosuppressive effect of immunosuppressants
abatacept
it may enhance the immunosuppressive effect of immunosuppressants
saquinavir
may enhance the serum concentration of P-glycoprotein inhibitors
pidotimod
may decrease the therapeutic effect
olaparib
may increase the toxic effect of myelosuppressive effect
edoxaban
may enhance the serum concentration
clozapine
may increase the toxic effect of the myelosuppressive effect
alpelisib
may decrease the serum concentration
aliskiren
may enhance the serum concentration
netupitant
when netupitant is combined with abrocitinib, it can lead to a reduced metabolism of abrocitinib
mibefradil
The combination of mibefradil and abrocitinib can lead to an increase in the concentration serum of mibefradil
antipyrine
antipyrine with abrocitinib could potentially lead to a reduce in the metabolism of abrocitinib.
pranlukast
Combining abrocitinib with pranlukast may cause a reduction in the abrocitinib’s metabolism
nimesulide
It may enhance the risk of bleeding when combined with nimesulide
ozanimod
may have an increased immunosuppressive effect when combined with immunosuppressants
fingolimod
may have an increased immunosuppressive effect when combined with immunosuppressants
ponesimod
may have an increased immunosuppressive effect when combined with immunosuppressants
methotrexate
may enhance the risk of serious infection by increasing immunosuppressive effect of methotrexate
pemetrexed
interaction may raise the risk of serious infections due to immunosuppressive effects
decitabine
may increase excessive immunosuppressive effects
pidotimod
may decrease the therapeutic effect when combined with pidotimod
brincidofovir
may decrease the therapeutic effect when combined with brincidofovir
Minor
Adult
Pediatric
Geriatric
Dosage Forms & Strengths
Tablet
50mg
100mg
200mg
Atopic Dermatitis
100
mg
Tablet
Orally
every day initially
Dosage Forms & Strengths
Safety and efficacy not established
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: abrocitinib
Pronounced : [ A-broe-SYE-ti-nib]
Why do we use abrocitinib ?
It is used to treat atopic dermatitis(eczema)
